Concepedia

Timothy Crowder

TC

Statistics

Publications

3

Citations

85

H-Index

3

Active since

2017

Affiliations

Spyryx Biosciences (United States)(Current)

Lung Institute

Timothy Crowder is an author at Spyryx Biosciences (United States) specializing in clinical trials, immunology, and medicine.

Top concepts

Publications per year

2017–2019

3

Publications

3

SPX-101 Is a Novel Epithelial Sodium Channel–targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport

David W. Scott, Matthew P. Walker, Juliana I. Sesma et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 53 citations

First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis

Peter Couroux, Paulina Farías, Leena Rizvi et al. · Pulmonary Pharmacology & Therapeutics · 2019 · 20 citations

, , +5

Nonclinical safety assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the treatment of cystic fibrosis

Matthew P. Walker, Matt Cowlen, Dale J. Christensen et al. · Inhalation Toxicology · 2017 · 12 citations

1–3 of 3